DBV Technologies reported $-41875000 in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amarin USD -15697000 32.92M Mar/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
DBV Technologies USD -41875000 14.8M Jun/2025
Halozyme Therapeutics USD 165.16M 47.06M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Insmed USD -321686000 65.1M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
PTC Therapeutics USD -64849000 931.41M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
United Therapeutics USD 309.5M 12.7M Jun/2025